CD8A and neoplasm: Like other intracellular proteins, the truncLT is processed in the cytoplasm and presented on major histocompatibility complex (MHC; also termed human leukocyte antigen, HLA in humans) class I to cytotoxic CD8+ T-cells, giving rise to diverse peptide epitopes, which can be recognised by T-cells and cause an immune response against the tumour.